Berenberg starts Genus at 'buy', cites protein demand and China opportunity
Analysts at Berenberg initiated coverage on genetics firm Genus Plc with a 'buy' rating and a 3,050p target price on Wednesday, stating the "long-term underlying dynamics" of the business "look attractive".
Berenberg said the combination of rising population growth and increasing urbanisation, most notably in developing markets, had created "a substantial increase in demand" for protein in recent years, which it thinks looks set to continue.
"With Genus focused on increasing the productivity and efficiency with which this protein is produced, the long-term drivers underpinning the business model look strong," said Berenberg, which also noted that Genus looked "well positioned to benefit" from the consolidation and professionalisation of the farming industry.
The German bank also believed that China represents "a substantial medium-term opportunity" for Genus, given the current low level of genetic sophistication in the country's farming industry.
Berenberg added that Genus' "potentially transformative" gene editing technology offers "significant medium term upside" beyond its current estimates, in our view.
"Genus trades at 18.4x 2027E EV/EBIT and 23.1x P/E. We value Genus using a DCF for the core business, before adding a discounted and probability-weighted valuation of the company's gene editing programme," said Berenberg.
Reporting by Iain Gilbert at Sharecast.com
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
